Search PubMed⌕ Search

PubMed · 2642158

Urothelial malignancy.

Abstract

Urothelial malignancy fascinates the urologist by the range of problems it presents. In superficial bladder cancer, we have reduced the demands of treatment by using fibrescopic technology to make outpatient treatment comfortable and acceptable to our patients. We have adopted a policy of radiotherapy and salvage cystectomy to try to preserve bladder and sexual function in our patients with invasive bladder cancer. The results of recent histological studies may help us to predict which patients will respond to radiotherapy so that we can offer alternative treatment to those who will not. At present, the endoscopic management of tumours of the upper urinary tract poses technical difficulties which will resolved only after further advances in technique and instrumentation.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C G Fowler. 1989. Urothelial malignancy.. https://pubmed.ncbi.nlm.nih.gov/2642158/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Trimodality treatment and selective organ preservation for bladder cancer.

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment, including transurethral resection of the bladder tumor (TURBT), radiation therapy and chemotherapy, has been shown to produce survival rates comparable to those of cystectomy. With these programs, cystectomy has been reserved for patients with incomplete response or local relapse. During the past 15 years, organ preservation by trimodality treatment has been investigated in prospective series from single centers and cooperative groups, with more than 1,000 patients included. Five-year overall survival rates in the range of 50% to 60% have been reported, and approximately three quarters of the surviving patients maintained their bladder. Clinical criteria helpful in determining ideal patients for bladder preservation include early tumor stage (including high-risk T1 disease), a visibly complete TURBT, and absence of ureteral obstruction. Close coordination among all disciplines is required to achieve optimal results. Future investigations will focus on (1) optimizing radiation techniques and incorporating more effective systemic chemotherapy, and (2) the proper selection of patients based on molecular makers.

Carcinoma, Transitional Cell↗